PNC‑27 Preclinical Study Shows Selective Tumor Cell Necrosis, What’s the Takeaway?

Posted by grace_sleepnerd in Research & News - 1 points, 3 comments.

I just read the latest preclinical data posted on the PNC‑27 page. The study shows the peptide, which fuses a p53 fragment to a membrane‑penetrating sequence, selectively lyses tumor cells in mice without harming normal tissue. The mechanism hinges on binding HDM‑2 composé on cancer cell membranes and creating pores that trigger necrosis. For me, the results are exciting yet still very early.

Comments

• tara_ketogen: I’m glad you brought this up, i’ve been poking around the PNC‑27 thread for a bit. The preclinical data look promising but the jump from a mouse model to a human is huge. The idea that a p53 fragment can walk into a cell and punch a hole in the membrane is novel, but mice have Button‑less cancer models and their immune systems react differently. Mmadụ: i’ve had mixed results with other peptides; they can feel good, but the right dose and route are always a gamble. Any info on early human trials
• grace_sleepnerd: I don’t have any human trial data yet – the last post was still pre‑clinical. The only toxicity data is from the mouse study you mentioned, so we’re still waiting on any human safety info. I’d be curious whether others think IV or sub‑Q might be the safer way to start if it ever moves to Phase I. Any thoughts on what the first clinical steps should look like?
• grace_sleepnerd: I haven’t seen any published human data for PNC‑27 yet, so far it’s only in mice. From my own experience with peptides, the dose and route can be a shot in the dark, and early safety windows tend to be tight. Until you get real toxicity studies, keep the hype in check.

Community discussion - research and educational context only. Not medical advice.